Spasticity increases during pregabalin withdrawal.

PRIMARY OBJECTIVE: To determine whether pregabalin produces long-term spasticity reduction in subjects previously identified as responding in short-term trials. DESIGN, SUBJECTS AND SETTING: Prospective service evaluation of patients taking pregabalin for spasticity management for at least 1 year through a tertiary referral rehabilitation clinic. A graduated pregabalin withdrawal was undertaken as part of routine clinical management. METHOD: Twelve of 19 potential subjects agreed to participate. The primary outcome measures were visual analogue pain and spasticity scores at lowest dose of pregabalin compared to baseline and their choice to resume pregabalin therapy. RESULTS: Mean pre-withdrawal pregabalin dosage was 386 mg/day, decreasing to 70 mg/day at mean lowest dosage. Median subjective spasticity scores increased from 4 at baseline to 6 at lowest dose (p < 0.01) without a significant increase in median pain scores. Two patients with epilepsy, whose other anti-convulsants were not altered, had seizures. Following the evaluation, five subjects chose to return to the original dose, five recommenced pregabalin at a lower dose and two subjects no longer required the drug. CONCLUSION: Pregabalin withdrawal resulted in self-reports of increased spasticity without a concomitant increase in pain, with 91% choosing to continue pregabalin at the conclusion of the evaluation.

Pregabalin in the treatment of spasticity: a retrospective case series.

PURPOSE: To evaluate the therapeutic effects of the GABA analogue, pregabalin, on patients with conditions producing spasticity who had not responded to, or experienced problems with side-effects of the available anti-spasticity agents. METHOD: A retrospective case series review of 22 patients who were prescribed open label Pregabalin as monotherapy for spasticity, starting with 75 mg bd and increasing to 300 mg bd. Twenty one of these patients had previously tried gabapentin, 19 had tried baclofen, 7 had tried tizanidine and 3 had tried dantrolene. RESULTS: Twelve patients perceived a definite reduction in symptoms of spasticity with pregabalin, and 9 continued to take it. Eight patients experienced significant side-effects which limited its use, 5 experienced no beneficial or adverse effects. CONCLUSIONS: Pregabalin may be of value as a systemic agent in the treatment of spasticity, although properly controlled studies with clearly defined outcome measures are required to confirm this finding. This is relevant to the study of disability and rehabilitation because of the difficulties encountered in the management of spasticity and the impact that this can have on the rehabilitation of individuals with neurological conditions.

Combined transcranial direct current stimulation and robot-assisted arm training in subacute stroke patients: a pilot study.

BACKGROUND AND PURPOSE: Preliminary reports suggest that central stimulation may enhance the effect of conventional physical therapies after stroke. This pilot study examines the safety and methodology of using transcranial direct stimulation (tDCS) with robot-assisted arm training (AT), to inform planning a larger randomised controlled trial. SUBJECTS: Ten patients, after an ischaemic stroke 4-8 weeks before study onset, no history of epilepsy, participated. Eight had a cortical lesion and 2 had subcortical lesions: all had severe arm paresis and, co-incidentally, 5 had severe aphasia. METHODS: Over six weeks, they received thirty 20 min-sessions of AT. During the first 7 minutes, 1.5mA of tDCS was applied, with the anode over the lesioned hemisphere and the cathode above the contralateral orbit. Arm and language impairment were assessed with the Fugl-Meyer motor score (FM, full range 0-66) and the Aachener Aphasie Test. RESULTS: No major side effects occurred. Arm function of three patients (two with a subcortical lesion) improved significantly, with FM scores increasing from 6 to 28, 10 to 49 and 11 to 48. In the remaining seven patients, all with cortical lesions, arm function changed little, FM scores did not increase more than 5 points. Unexpectedly, aphasia improved in 4 patients. CONCLUSIONS: These procedures are safe, and easy to use in a clinical setting. In future studies, patients should be stratified by degree of arm weakness and lesion site, also the unexpected aphasia improvement warrants following-up.

The Papworth Early Rehabilitation Programme: vocational outcomes.

BACKGROUND: There are 2.7 million people in the UK receiving incapacity benefits, costing approximately pound 18 billion pa. Government has adopted a policy of helping claimants back into work, through structured vocational rehabilitation schemes. There are no published results of vocational rehabilitation services in the UK. We present the results of the Papworth Trust vocational rehabilitation programme. Depending on the severity of their disability, the 'Early Rehab Programme' aims to get people on incapacity benefits: (a) into employment, (b) fit for and seeking work, (c) involved in voluntary work, (d) education, or (e) able to live independently. METHODS: Retrospective chart survey and telephone follow up. SETTING: Cambridgeshire. RESULTS: Since 1995, 274 people attended for a preliminary interview, of which 107 subsequently started a full rehab programme. Eighty-seven were male and 20 female. Half had been unemployed for more than two years. Ninety-four completed the programme, of whom 53 had gained employment, 33 were 'work ready' and four were doing voluntary work. At long-term follow-up, 52 were employed, 12 were in voluntary work, and 7 had retired on medical grounds. CONCLUSIONS: This programme demonstrates that long-term Incapacity Benefit recipients can return to sustained employment, as shown in those who participated in the Papworth Trust's vocational rehabilitation programme.

Secondary prevention of arteriosclerosis in lower limb vascular amputees: a missed opportunity.

OBJECTIVES: To determine the numbers of patients with peripheral vascular disease prescribed secondary prevention agents following a lower limb amputation. DESIGN: A retrospective cross sectional study. METHODS: The clinical documentation of 107 vascular amputees (mean age 69.5, 2:1 male:female ratio) referred for prosthesis provision in 2004 and 2005 were analysed to determine levels of prescribing of anti-platelet agents, anti-coagulants and cholesterol lowering drugs. RESULTS: Analysis of vascular amputees referred in 2004 and 2005 reveals that 41% were prescribed a statin and 39% were prescribed a statin and 60% an anti-platelet agent. While 39% of these patients were on both drugs, 32% had been prescribed neither. CONCLUSIONS: The medical management of patients with severe peripheral vascular disease, even where their disease has led to an amputation, is sub-optimal.

Inappropriate acute neurosurgical bed occupancy and short falls in rehabilitation: implications for the National Service Framework.

Patients undergoing neurosurgical intervention may require different types of organized rehabilitation. A prospective study was performed of the care needs of neurosurgical inpatients between the ages of 16 and 70 years who were in acute wards for more than 2 weeks. Only 58% of bed occupancy days were devoted to essential acute neurosurgical ward management. This figure was even lower for patients admitted with subarachnoid haemorrhage (36%) or traumatic brain injury (38%). Overall, 21% of bed days would have more appropriately spent in 'rapid access'/acute rehabilitation beds, 13% in 'active participation' rehabilitation beds and 5% in cognitive/behavioural rehabilitation units. Addressing this unmet need would increase the availability of acute neurosurgery beds, without needing to build and staff more neurosurgery wards.

Current practice of prophylactic anticoagulation in Guillain-Barré syndrome.

OBJECTIVE: To document the incidence of venous thromboembolism in Guillain-Barré syndrome and current practice of anticoagulating these patients. DESIGN: Retrospective study. SETTING: Acute neurology and rehabilitation wards in a teaching hospital. SUBJECTS: Seventy-three patients with Guillain-Barré syndrome admitted to Addenbrooke's Hospital from 1995 to 1999. RESULTS: Out of 73 patients, 50 were anticoagulated (68%) for 5-490 days with mean of 72 days. Anticoagulation was discontinued in 28 patients when they could walk independently and in six who were still wheelchair dependent. Five patients developed clinical deep venous thrombosis (DVT) (7%), three of them had pulmonary emboli. Venous thrombosis occurred in the first two months after onset in four patients. Two patients were not anticoagulated when they developed their DVT and the other three were on enoxaparin; one of these three had a pulmonary embolism and died. CONCLUSION: Despite prophylactic anticoagulants being used in the majority of patients admitted with major problems of mobility, 6% (3 out of 50) still developed clinically detected DVT and two developed pulmonary embolism. While this incidence is considerably lower than data reported before routine anticoagulation became a standard practice, these data reinforce the need for anticoagulation and suggest that full anticoagulation might be needed to reduce the incidence of thromboembolic complications further.